CRISPR Therapeutics CRSP Accounts payable and other current liabilities
Accounts payable and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's accounts payable and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's accounts payable and other current liabilities?
- CRISPR Therapeutics (CRSP) reported accounts payable and other current liabilities of -$13.02M in Q1 2026.
- How has CRISPR Therapeutics's accounts payable and other current liabilities changed year-over-year?
- CRISPR Therapeutics's accounts payable and other current liabilities decreased by 130.3% year-over-year, from $43M to -$13.02M.
- What is the long-term trend for CRISPR Therapeutics's accounts payable and other current liabilities?
- Over 2 years (2021 to 2024), CRISPR Therapeutics's accounts payable and other current liabilities has grown at a -14.7% compound annual growth rate (CAGR), from $37.51M to -$27.28M.